218.3 ð©º å §ç§å°ç§èåç
218.3.0.1 1ïžâ£ When to Start ART in OI Setting
- Most OIs: within 2 weeks of OI treatment start
- Cryptococcal meningitis: delay 4-6 weeks (COAT trial â high IRIS mortality if early)
- TB: depends on CD4
- CD4 < 50: within 2 weeks
- CD4 50-200: within 2-8 weeks
- CD4 > 200: within 8-12 weeks
- CNS TB: delay 4-8 weeks (IRIS risk)
- CMV retinitis: start ART promptly with treatment
218.3.0.2 2ïžâ£ COAT Trial (Cryptococcal ART Timing)
- Earlier ART (within 2 wk) â high mortality in CrAg+ patients
- Delayed ART (4-6 wk) â better survival
- Standard now: delay 4-6 weeks
- Especially relevant for low- and middle-income countries
218.3.0.3 3ïžâ£ Steroid in OIs
| OI | Steroid Indication |
|---|---|
| PJP | A-a > 35 or PaO2 < 70 â reduce mortality |
| Toxoplasmosis | Mass effect / edema |
| Cryptococcal meningitis | Not routine; IRIS severe; CSF pressure management priority |
| TB meningitis | All TBM (reduces mortality) |
| PML-IRIS | Severe inflammation |
| Cardiac tamponade pericardial TB | All effusions |
218.3.0.4 4ïžâ£ TMP-SMX Intolerance
- Allergic rash (10-15% HIV+)
- Marrow suppression
- Hyperkalemia, AKI
- Alternative: dapsone (G6PD screen), atovaquone, pentamidine inhaled
- Desensitization protocol if previous reaction
218.3.0.5 5ïžâ£ Pediatric HIV + OIs
- Same CD4-based prophylaxis (using % rather than absolute count)
- Maternal PJP prophylaxis during pregnancy
- Infants 4-6 wk post-delivery
- TMP-SMX standard
- BCG vaccination decisions (avoid in HIV-exposed infant if not yet treated)
218.3.0.6 6ïžâ£ ICI (Immune Checkpoint Inhibitor) in HIV
- ART + ICI for cancer treatment
- Generally well-tolerated
- ICI may have impact on HIV reservoir (research ongoing)
- IRIS-like immune-mediated adverse events
218.3.0.7 7ïžâ£ å¥ä¿ / Taiwan
- å¥ä¿ OI prophylaxis (TMP-SMX, fluconazole, valganciclovir, etc.)
- å¥ä¿ ART covered universally
- HIV + OI hospital admission protocols
- ç§é«åž« hint: è HIV+ ç 人 â comprehensive OI prevention + vaccines + ART optimization; new HIV diagnosis CD4 < 200 â admission to start ART + OI prophylaxis
218.3.0.8 8ïžâ£ Coccidioidomycosis Lifelong Prophylaxis
- HIV + endemic SW USA exposure
- CD4 < 250 â fluconazole 400 mg/d
- Possible lifelong (high relapse rate)
- Risk reduction with masks + dust precautions